Vir Biotechnology Inc - Asset Resilience Ratio
Vir Biotechnology Inc (VIR) has an Asset Resilience Ratio of 20.57% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Vir Biotechnology Inc (VIR) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Vir Biotechnology Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Vir Biotechnology Inc asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Vir Biotechnology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Vir Biotechnology Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $249.86 Million | 20.57% |
| Total Liquid Assets | $249.86 Million | 20.57% |
Asset Resilience Insights
- Good Liquidity Position: Vir Biotechnology Inc maintains a healthy 20.57% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Vir Biotechnology Inc Industry Peers by Asset Resilience Ratio
Compare Vir Biotechnology Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Vir Biotechnology Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Vir Biotechnology Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 22.81% | $228.75 Million | $1.00 Billion | -25.97pp |
| 2024-12-31 | 48.78% | $682.40 Million | $1.40 Billion | -17.96pp |
| 2023-12-31 | 66.74% | $1.28 Billion | $1.92 Billion | +11.31pp |
| 2022-12-31 | 55.44% | $1.55 Billion | $2.80 Billion | +37.00pp |
| 2021-12-31 | 18.44% | $360.33 Million | $1.95 Billion | -14.25pp |
| 2020-12-31 | 32.68% | $300.29 Million | $918.76 Million | -20.84pp |
| 2019-12-31 | 53.53% | $274.10 Million | $512.07 Million | +26.99pp |
| 2018-12-31 | 26.54% | $50.84 Million | $191.60 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $251.57 Million | -- |
About Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those ta… Read more